Transforming lives with safer, more effective therapies.
CX-2029, a PROBODY Drug Conjugate Targeting CD71 (Transferrin Receptor): Results From a First-in-Human study (PROCLAIM-CX-2029) in Patients With Advanced Cancer
Melissa Johnson, Anthony El-Khoueiry, Navid Hafez, Nehal Lakhani, Hirva Mamdani, Jordi Rodon, Rachel E. Sanborn, Thang Ho, Rachel Li, Jana Waldes, Alexander I. Spira. Oral presentation at the ASCO20 Virtual Scientific Program, May 29-31, 2020.